News

Both the companies are negotiating an exclusive worldwide license that would result in Cannasat assuming product development and commercialisation rights to APL-130277 from Adagio in return for development

The study was conducted in approximately 100 clinical sites throughout North America and Europe. The company plans to use data from the study to support submission of a

The candidate is produced through a proprietary process using a new growth environment that promotes faster maturation than chicken eggs, the standard environment since 1943. The phase II

ISC’s facility consists of separate suites for development and production of different cell types from the company’s proprietary human parthenogenic stem cell (hpSC) technology. The company has established

Decapeptyl LP 22.5mg is available as 1-3 months sustained release formulations and also daily formulation. Decapeptyl releases hormone (GnRH) agonist analogue over a period of time. The company

The company has also reported that it has designed a Phase 1/2 clinical trial to evaluate the safety of ARQ 197 administered in combination with irinotecan and cetuximab

Reportedly, in 2006, Aradigm has sold all assets related to the Intraject needle-free injector technology (now rebranded as DosePro) to Zogenix in exchange for milestone and royalty payments.

As per the agreement, Genmab is expected to receive an up-front license fee of $4.5m and will be entitled to milestones and royalties on sales of zanolimumab. TenX

BTG has a licensing agreement with Beacon Pharmaceuticals for the marketing of DigiFab in Europe, and Beacon has sub-licensed DigiFab distribution in Switzerland to Proreo Pharma. DigiFab has